## Addressing Escalating Agitation in Dementia: Emerging Treatments and a Holistic Approach
Dementia-related agitation presents a considerable clinical hurdle, impacting both patient well-being and caregiver burden. For years, clinicians have navigated this challenge with limited FDA-approved therapeutic options and faced cautionary warnings regarding the use of conventional medications.Recent data indicates that approximately half of individuals with Alzheimer’s disease experience some form of agitation or aggression, a factor demonstrably linked to accelerated cognitive decline and diminished functional capacity.### The Historical Treatment Gap & Associated Risks
Historically, the pharmacological management of agitation in dementia has been fraught with difficulty. Standard treatments like selective serotonin reuptake inhibitors (SSRIs) have demonstrated limited efficacy, while benzodiazepines have largely proven ineffective in addressing the core symptoms. Furthermore, the use of antipsychotics – often employed off-label – carried notable risks, including heightened mortality rates and an increased incidence of cerebrovascular events, prompting stringent “black box” warnings from regulatory bodies. This created a critical need for safer,more targeted interventions.
### A Shifting Paradigm: New Pharmaceutical Developments
the therapeutic landscape is now evolving. In May 2023,the FDA approved brexpiprazole (Rexulti),available in dosages of 2-3mg daily,specifically for the treatment of agitation associated with Alzheimer’s disease. 2 This approval marks a significant step forward, offering a medication designed to address the specific neurochemical imbalances underlying agitation. Brexpiprazole’s mechanism of action involves modulating activity across three key monoamine systems – noradrenergic, serotonergic, and dopaminergic – offering a multi-faceted approach to symptom management.
Beyond brexpiprazole, promising research is underway. AXS-05, a combination of bupropion and dextromethorphan, has shown encouraging results in several clinical trials, including the pivotal ADVANCE and ACCORD studies, with positive outcomes observed in three out of four trials. This suggests a potential future addition to the treatment arsenal.
### Beyond Medication: A Comprehensive Assessment is key
While new pharmacological options are emerging, a holistic and cautious approach remains paramount. Before initiating any medication, a thorough evaluation to identify and address underlying contributing factors is essential. Clinicians must consider whether environmental changes, such as relocation or alterations in routine, are triggering the agitation. Unmanaged pain, frequently enough under-recognized in dementia patients, and co-existing medical conditions – including infections and metabolic imbalances – must be systematically ruled out. It’s crucial to determine if the agitation is a symptom of an unmet need, rather than a primary neurological issue. Consider, for example, whether a patient is experiencing discomfort due to constipation or dehydration, which can manifest as behavioral disturbance.
### The importance of Early Intervention and Quality of Life
Prompt and effective management of agitation is not merely about symptom suppression; it’s about preserving quality of life and delaying the need for more intensive care. Agitation is independently associated with poorer outcomes for individuals with dementia. By proactively addressing agitation, clinicians can help patients maintain independence, remain connected with loved ones, and experience a greater sense of well-being for a longer duration. Prioritizing interventions that allow individuals to remain in familiar home environments, surrounded by family support, is a cornerstone of compassionate dementia care.2 FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease. Press release. May 11, 2023. Accessed July 12, 2025.